1 Patient Clusters and Cost Trajectories in Atrial Fibrillation:

2 Evidence from the Swiss Atrial Fibrillation Cohort

- 3 Authors
- 4 Aebersold Helena^a, Serra-Burriel Miguel^a, Foster-Witassek Fabienne^a, Moschovitis
- 5 Giorgio^b, Aeschbacher Stefanie^{c,d}, Auricchio Angelo^e, Beer Jürg H.^{f,g}, Blozik Eva^h, Bonati
- 6 Leo H.i, Conen Davidk, Felder Stefan, Huber Carola A.m, Kühne Michaelc, Müller
- 7 Andreasⁿ, Oberle Jolanda^{o,p}, Paladini Rebecca E.^{c,d}, Reichlin Tobias^q, Rodondi
- 8 Nicolas^{o,p}, Springer Anne^{c,d}, Stauber Anninaⁿ, Sticherling Christian^{c,d}, Szucs Thomas^r,
- 9 Osswald Stefan^{c,d}, Schwenkglenks Matthias^{a,r}, on behalf of the Swiss-AF Investigators
- ^a Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich,
- 12 Switzerland

10

- 13 b Division of Cardiology, Ente Ospedaliero Cantonale (EOC), Ospedale Regionale di
- 14 Lugano, Lugano, Switzerland
- 15 ° Cardiology Division, Department of Medicine, University Hospital Basel, Switzerland
- 16 d Cardiovascular Research Institute Basel, University Hospital Basel, Switzerland
- 17 ^e Department of Cardiology, Instituto Cardiocentro Ticino, Ente Ospedaliero Cantonale
- 18 (EOC), Lugano, Switzerland
- 19 f Department of Medicine, Cantonal Hospital of Baden, Switzerland
- 20 ^g Center for Molecular Cardiology, University of Zürich, Switzerland
- 21 h Institute of Primary Care, University of Zurich, Zurich, Switzerland
- 22 Department of Neurology, University Hospital Basel, Basel Switzerland
- 23 ^j Research Department, Reha Rheinfelden, Rheinfelden, Switzerland
- ^k Population Health Research Institute, McMaster University, Hamilton, Canada
- 25 University of Basel, Faculty of Business and Economics, Switzerland
- ^m Department of Health Sciences, Helsana Group, Zurich, Switzerland
- ⁿ Department of Cardiology, Triemli Hospital Zurich, Switzerland
- 28 ° Institute of Primary Health Care (BIHAM), University of Bern, Switzerland
- 29 P Department of General Internal Medicine, Inselspital, Bern University Hospital,
- 30 University of Bern, Switzerland
- 31 ^q Department of Cardiology, Inselspital, Bern University Hospital, University of Bern,
- 32 Switzerland

- ¹ Institute of Pharmaceutical Medicine (ECPM), University of Basel, Basel, Switzerland
- 35 **Correspondence**:
- 36 NOTE THIS PROPRIED TO SHOW research that has not been certified by peer review and should not be used to guide clinical practice.

- 1 University of Zurich
- 2 Epidemiology, Biostatistics & Prevention Institute (EBPI)
- 3 Hirschengraben 84, 8001 Zurich
- 4 <u>helena.aebersold@uzh.ch</u>
- 6 Word count:
- 7 2993

Abstract

Aims

Evidence on long-term costs of atrial fibrillation (AF) and associated factors is scarce. As part of the Swiss-AF prospective cohort study we aimed to characterise AF costs and their development over time, and to assess specific patient clusters and their cost trajectories.

Methods

Swiss-AF enrolled 2,415 patients with variable duration of AF between 2014 and 2017. Patient clusters were identified using hierarchical cluster analysis of baseline characteristics. Ongoing yearly follow-ups include health insurance clinical and claims data. An algorithm was developed to adjudicate costs to AF and related complications.

Results

Hierarchical analysis identified three patient clusters. "Cardiovascular-dominated" (CV-dominated) patients had the highest proportions of prior myocardial infarction and presence of diabetes. "Heart failure-dominated" (HF-dominated) patients had the highest occurrence of heart failure and permanent AF. "Isolated symptomatic" (IS) patients were younger and had the highest occurrence of paroxysmal AF. A subpopulation of 1,024 Swiss-AF patients with available claims data was followed up for a median [interquartile range] of 3.24 [1.09] years. Average yearly AF-adjudicated costs amounted to CHF 5,679, remaining stable across the observation period. CV-dominated (N = 253 with claims data) and HF-dominated patients (N = 185) depicted similarly high costs across all cost outcomes, the IS (N = 586) patients accrued the lowest costs.

Conclusion

Our results highlight three well-differentiated patient clusters with specific costs that could be used for stratification in both clinical and economic studies. Patient characteristics associated with adjudicated costs as well as cost trajectories may enable an early understanding of the magnitude of upcoming AF-related healthcare costs.

Keywords

atrial fibrillation, cost of illness, cost trajectories, hierarchical clustering, patient cluster

What is already known on this topic

- 2 Atrial fibrillation (AF) is a complex disease and constitutes a major economic and
- 3 societal challenge due to its high prevalence worldwide.

What this study adds

1

4

5

9

10

14

- 6 This study, based on a large prospective cohort study, provides evidence on real-world
- 7 AF costs and their development over time. Data-derived patient clusters are linked to
- 8 costs and their respective cost trajectories are assessed.

How this study might affect research, practice or policy

- 11 The identified patient clusters and their characteristics may help clinicians and payers to
- 12 gain an early insight and understanding of the magnitude of the expected AF-related
- 13 healthcare costs.

Introduction

Atrial fibrillation (AF) is the most prevalent arrhythmia worldwide,¹ and its prevalence is expected to double by 2050.^{2,3} AF patients face increased risk of stroke, cognitive dysfunction, and impaired quality of life.^{4,5}

AF also constitutes a major economic and societal challenge. However, only a limited number of AF cost-of-illness studies⁶ is available, indicating that costs are predominantly driven by AF-related hospitalisations.⁷ Hospitalisation costs were reported to amount to 50-70% of total costs,⁸ while medication costs were comparatively low.⁹ Drivers of hospitalisations in AF patients were identified to be multifaceted and diverse.^{10,11} They include age, cardiovascular diseases like previous history of heart failure and myocardial infarction, non-cardiovascular conditions, i.e. sleep apnoea and chronic kidney disease, as well as lifestyle factors.

Despite these insights, evidence on real-world AF-related costs and their components remains scarce. Most results stem from retrospective studies. Even less evidence is available on cost trajectories over time, especially in prevalent AF patients. Patient characterisation based on AF subtypes is known to not encompass the full heterogeneity of AF,^{12,13} and data-driven characterisation of patients has not yet been used for costing.

The Swiss-AF Economics project is part of the prospective Swiss Atrial Fibrillation cohort study^{14,15} (Swiss-AF) and aims to assess AF-related economic burden. Clinical data are combined with health insurance claims data to characterise the Swiss-AF study population from an economic perspective. Focusing on the direct medical cost per patient from the perspective of the Swiss statutory health insurance system, the present work aims to: i) describe AF costs and their trajectories, and ii) to build data-driven patient clusters and assess their respective cost trajectories.

Methods

Study Design and Data Sources

Swiss-AF is an ongoing prospective multicentre observational cohort study across 13 clinical centres in Switzerland. The detailed study setup and methodology have been described earlier. In short, 2,415 patients were enrolled between April 2014 and August 2017; this analysis used a 2014-2020 data cut. Eligibility criteria for Swiss-AF were based on a history of documented AF (paroxysmal, persistent, or permanent) and being older than 65 years; 228 patients were enrolled at age 45-64 years to enhance the study of socio-economic aspects of AF.

Health economic data include medical resource use at the enrolling centres and health insurance claims data from four cooperating insurance companies, covering 1,024 patients (42.4% of the study population). The claims data cover all services submitted for reimbursement by the Swiss statutory health insurance. The statutory health insurance is obligatory for all residents and has a comprehensive benefit package covering inpatient and outpatient services. An insured person can choose from a variety of deductibles (CHF 300–2,500), where a higher deductible leads to a lower premium.

Claims relating to inpatient services were based on the Swiss flat-fee reimbursement scheme for acute care hospitalisations (SwissDRG¹⁶). Data related to inpatient services in rehabilitation clinics were based on tariffs per day negotiated between each service provider and insurer, and claims related to nursing home care services were based on daily contributions fixed by the Swiss Federal Council. Outpatient services were covered with detailed information for each cost component. Relevant comorbidities not collected by the Swiss-AF study were derived from the drug utilisation present in the claims data, using the pharmaceutical cost groups (PCGs) method.¹⁷

Outcome Measures

Our main outcome of interest was total AF-adjudicated costs from the Swiss statutory health insurance perspective. Costs in AF patients are typically partially related to AF and its potential complications, partially related to other comorbidities. To distinguish these components, an adjudication algorithm was developed through an iterative process involving several clinical experts of the Swiss-AF study centres. The adjudication algorithm (https://gitlab.uzh.ch/helena.aebersold/patient-clusters-and-cost-trajectories.git) combined clinical events, e.g. date of a bleeding event, with information from the health insurance claims, e.g. SwissDRG based. Inpatient costs were either non-related or adjudicated to one of five groups: (1) AF, (2) stroke or transient ischemic attack (TIA), (3) bleeding, (4) fall, (5) heart failure. Similarly, outpatient costs were either non-

- related or classified into one of six groups: (1) AF without medication, (2) AF medication,
- 2 (3) stroke or TIA without medication, (4) stroke or TIA medication, (5) bleeding, (6) fall.
- 3 As it was not possible to distinguish between complications (e.g. strokes) caused by AF
- 4 or other reasons, complication costs were considered in full.
- We thus considered the sum of all costs adjudicated to groups (1) to (6) as total
- 6 AF-adjudicated costs. Secondary outcomes included AF-adjudicated inpatient costs, AF-
- 7 adjudicated outpatient costs excluding drug costs, and AF-adjudicated outpatient drug
- 8 costs. We also considered total costs, i.e., the sum of total AF-adjudicated costs and
- 9 total non-adjudicated costs, and equivalent sub-categories. All outcome variables and
- their relation can be found in **Figure S1** in the supplement.
- 11 Covariates

1

- 12 Baseline covariates, measured at enrolment, included the following types:
- 13 (1) patient characteristics: age, sex, body mass index (BMI), AF type, AF symptoms, time
- since AF diagnosis, risk of stroke for non-valvular atrial fibrillation (CHA₂DS₂-VASc
- 15 score).
- 16 (2) medical history: previous major bleeding, stroke or TIA, systemic embolism, heart
- 17 failure, myocardial infarction, diabetes, hypertension, renal insufficiency, sleep
- 18 apnoea.
- 19 (3) treatments and implanted devices: percutaneous transluminal coronary angioplasty
- 20 (PTCA), coronary artery bypass grafting (CABG), electro-conversion, pulmonary vein
- 21 isolation (PVI), loop recorder, pacemaker (PM), cardiac resynchronisation therapy
- 22 (CRT) with or without ICD, implantable cardioverter defibrillator (ICD).
- 23 (4) anticoagulation medication: vitamin K antagonist (VKA), direct-acting oral
- 24 anticoagulant (DOAC).
- 25 (5) other medication: antiplatelets, aspirin, statins, diuretics, beta-blockers, digoxin.
- 26 (6) socioeconomic factors: education, greater area of residence, smoking, alcohol
- 27 consumption.

- Statistical analysis
- 30 First, the characteristics of the included Swiss-AF patients were described.
- 31 Baseline characteristics were presented with mean and standard deviation for normally
- 32 distributed variables, median and interquartile range for continuous non-normally
- 33 distributed variables, and N (%) for categorical ones. Kaplan-Meier curves of overall
- 34 survival were used to depict mortality and cohort attrition.
- 35 Second, the costs and their trajectories since enrolment were described. Cost
- 36 components are shown as bar charts and boxplot distributions of mean annual costs.
- 37 Cost trajectories are depicted as line plots with mean estimates and 95% confidence

intervals. All costs considered individual follow-up times and were aggregated to a yearly level. Given the relative stability of prices over the observation period, costs were taken as reported. Costs as a function of time since diagnosis were also explored graphically.

Third, to gain an understanding of different patterns in the Swiss-AF population, clusters of patients and their respective cost composition and cost trajectories were determined. A hierarchical cluster analysis was run. The unsupervised learning model¹⁸ considered the full Swiss-AF population and all baseline covariates except greater area of residence. Gower distances were used with a complete linkage method, choosing optimal clusters according to elbow and silhouette methods.¹⁸ Differences in baseline characteristics between patient clusters were compared with standardised mean difference, t-test for continuous and roughly normally distributed variables, Mann-Whitney U test for continuous non-normally distributed variables, and fisher's exact test for categorical variables. Cluster-specific overall survival was compared using Kaplan-Meier curves and age-adjusted cox regression. A complementary multivariable regression-based cost analysis is reported in the supplement (**Figures S7-S8**, **Tables S5-S8**).

A 5% significance level was pre-specified, and no multiple hypothesis testing adjustments were performed due to the exploratory nature of the study. Given the usage of baseline data and observed claims there were no missing data. The cost analyses conditioned on patients being alive. Data management, variable derivations and all statistical analyses were conducted using R version 3.6.3.

Results

Patient population

Out of 2,415 Swiss-AF patients, 1,024 (42.4%) had available claims data and were included in the cost analyses. Baseline characteristics are shown in Fehler! Verweisquelle konnte nicht gefunden werden.. The mean age at baseline was 73 ± standard deviation (SD) 8 years and 28% of the participants were female. On average, patients were diagnosed with AF 6.3 years prior to enrolment, and the majority had AF symptoms (62%). Patients without available claims data, additionally used in the hierarchical cluster analysis, had comparable characteristics (Fehler! Verweisquelle konnte nicht gefunden werden. in the supplement). **Figure S2** in the supplement depicts the average monthly cost evolution alongside the Kaplan-Meier curve of overall survival, across the full observation period of 2014 to 2020. For subsequent analyses, individual patient follow-up was censored at five years after enrolment (median follow-up: 3.24 years), given sparse data thereafter.

Cost structures and cost trajectories

Mean annual costs and cost trajectories for different cost outcomes are shown in **Figure 1**. More details on all cost outcomes and costs by time since AF diagnosis can be found in the supplement (**Tables S2**, **Figures S3-S4**). The average total per-patient costs amounted to CHF 19,037 yearly, of which roughly half corresponded to outpatient services. Inpatient costs appeared to be higher than outpatient costs only during the first year, remaining stable and at a similar level thereafter.

Total AF-adjudicated costs amounted to CHF 5,679 annually, roughly 30% of the total costs. AF-adjudicated costs consisted mainly of AF treatment costs (CHF 4,078), followed by costs of bleeding (CHF 696) and heart failure (CHF 494). As the total costs, the AF-adjudicated costs remained stable across the whole analysed period of five years. AF-adjudicated inpatient costs were higher than AF-adjudicated outpatient costs in the first year.

Patient clusters and their cost trajectories

A total of three hierarchical analysis-based clusters were identified to be optimal according to the elbow and silhouette methods. Baseline characteristics by cluster are shown in **Table 1**. Cluster-specific Kaplan-Meier curves of overall survival and results of age-adjusted cox regression are depicted in **Figure S5** and **Table S3**.

The first cluster included 253 patients and may be characterised as "cardiovascular dominated" (CV-dominated). Most patients in this cluster had previous PTCA or CABG (87%), and we observed the highest proportions of prior myocardial infarction (55%), heart failure (50%), and stroke or TIA (27%). There was also a high

presence of diabetes (38%), hyperlipidaemia (67%), and past smoking (63%). Until the five-year follow-up 55 (21.7%) were deceased and 11 (4.3%) lost.

The second cluster included 586 patients we characterise as being "isolated symptomatic" (IS). Patients in this cluster were the youngest among the three clusters (mean age: 71). They had the highest occurrence of paroxysmal AF (54%) and presence of AF symptoms (73%). However, they had fewer medical history items present, fewer comorbidities, low medication use, and had been diagnosed with AF more recently (mean years: 5.3). Until the 5-year follow-up 36 (6.1%) were deceased and 14 (2.4%) lost.

The third cluster included 185 "heart failure dominated" (HF-dominated) patients. These patients were characterised by the highest occurrence of permanent AF (45%), a high presence of heart failure (43%), and the highest proportion with a pacemaker (22%). Moreover, they featured the lowest presence of AF symptoms (42%), had practically no previous myocardial infarctions (2.2%), low prevalence of diabetes (21%), and low aspirin usage (9.7%). Many used diuretics (90%). Until the 5-year follow-up 35 (18.9%) were deceased and 12 (6.5%) lost.

Cost trajectories for each cluster are shown in **Figure 2**. More details on the cost outcomes by cluster can be found in **Table S4** and **Figure S6**. Throughout all cost trajectories, the IS patients accrued the lowest costs. Moreover, the pattern in the IS group resembled the overall cost trajectory (see **Figure 1**): after an initial high, all costs remained stable across the observation period. Compared to the HF-dominated cluster, the CV-dominated patients depicted slightly higher AF-adjudicated costs. The results are consistent with the results of the complementary multivariable regression-based cost analysis, which provided estimates of average covariate effects across all patients (**Figures S7-S8**, **Tables S5-S8**).

Discussion

This study presents recent evidence on real-world AF costs. To the best of our knowledge, it is the first to link data-derived patient clusters with cost trajectories. We observed mean annual and AF-adjudicated healthcare costs to remain stable over several years. Furthermore, among three clinically well-differentiated patient clusters cost levels differed but were also stable throughout the observation period.

Mean annual total costs amounted to CHF 19,037 per AF patient (~23% of the Swiss Gross Domestic Product per capita), whereof CHF 5,679 were attributable to AF and its complications. Across the entire observation period, these costs remained relatively stable. Inpatient and outpatient costs were of similar magnitude; this applied to both, AF-adjudicated and non-adjudicated costs. This finding is in line with existing literature, where inpatient costs incurred at least half of the total costs. The observation of a stable proportion across five years, also apparent in AF-adjudicated costs, has not been previously described.

Of the AF-adjudicated costs, 71.8% were directly related to AF, followed by bleeding, heart failure, fall, and stroke / TIA costs. In the literature so far, AF-related costs were mostly assessed through various excess cost calculations²³ and a clinically-based bottom-up approach was missing. Even though our adjudication algorithm was unable to distinguish between the costs of care episodes triggered by AF versus by other causes, we believe that this bottom-up approach contributes to a more realistic understanding of AF and related costs. Also, in contrast to most studies, ^{19,21,24,25} our observed contribution of AF-adjudicated costs to overall healthcare costs was smaller. One reason may be that we analysed prevalent AF patients while the literature focussed mainly on incident patients.

Three well-differentiated patient clusters resulted from our analysis, with distinct cost trajectories: CV-dominated with rather high costs, HF-dominated with similarly high costs, and IS with substantially lower costs. Some attempts to cluster the heterogeneity of AF patients were reported previously, but not linked with cost trajectories. ^{12,26–28} To facilitate an understanding of expected patient trajectories, we based our analysis on baseline characteristics.

Our first cluster, the CV-dominated patients, featured many strong risk factors for cardiovascular diseases (e.g., high rates of past smokers, low rate of never smokers, high prevalence of diabetes) and high cardiovascular drug use (i.e. aspirin, statin, and beta-blocker). The high rates of cardiovascular revascularisation procedures, myocardial infarction and stroke/TIA suggested underlying cardiovascular disease. These characteristics are roughly comparable with those of the Atherosclerotic Comorbid AF cluster found in two other cluster studies. 12,26 The CV-dominated patients accrued

substantial costs, especially AF-adjudicated costs, which remained stable at a high level across time. This result is strongly consistent with the complementary multivariate approach.

The second cluster, representing IS, showed the lowest costs among the three clusters. Patients were noticeably younger, had fewer comorbidities, but high rates of previous cardioversion, AF symptoms, and paroxysmal AF. This cluster has partially similar characteristics as the Younger Paroxysmal AF cluster identified in a Japanese cohort²⁹ and the Low Comorbidity cluster identified in a US cohort¹². Differences in cultural and clinical settings, and in available descriptors of patient characteristics may have limited the degree of similarity. Considering the results of the multivariable regression-based analysis, this cluster seems to possess very few covariates that drive the costs significantly above a base level, explaining the low cost level.

The third cluster, HF-dominated, featured similarly high costs as the CV-dominated, as well as similarly high rates of heart failure. However, patients had almost no prior myocardial infarction, little diabetes, low aspirin intake, yet high diuretics intake. This may be consistent with heart failure caused by underlying causes other than cardiovascular disease. The patients also featured a relatively low prevalence of covariates associated with higher AF-adjudicated costs but were at the same cost level as the CV-dominated cluster. A possible explanation for this result may be unplanned hospitalisations and complications due to the ongoing challenge to treat patients with heart failure. This specific cluster has not yet been reported by other AF cluster studies. 12,26

The prospective cohort study patients we report on differ from the patient populations underlying recent AF costs studies in four ways, which has implication for the interpretation of the results. Firstly, most studies to-date relied on administrative databases^{21,25,30}; secondly, they were often retrospective^{19,21,25,27}; and thirdly, had short follow-up times between 0.5 to 3 years^{19,24,29}. In combining clinical and health insurance claims data prospectively, the present analysis adds detailed insight into the longer-term healthcare costs of AF patients. Fourthly, the present study examined prevalent patients with varying disease duration (including 13% enrolled within six months after first AF diagnosis). Even though the Swiss-AF study population cannot be regarded as a representative sample of AF patients, it provides insights on the longer-term cost impact of AF in a substantially wider spectrum of AF patients than previous studies.

There are several limitations inherent to our study that require discussion. First, the data structure is highly complex and patients in Swiss-AF are very heterogeneous. We tried to account for the heterogeneity with the clustering method, and covariate selection was based on the current literature as well as discussions with clinicians from

the Swiss-AF study centres. Second, as the study population is not truly representative of all Swiss AF patients, a typical 'average' AF cost could not be reliably deducted. Further work will approach this topic with a general population-based, matched control population. Third, given deductible levels in the Swiss statutory health insurance system, the possibility that not all claims were handed in for reimbursement exists, which may have led to an underestimation of true costs. However, as AF patients have substantial costs, it is rather unlikely that claims were not submitted. A fourth limitation lies in the adjudication algorithm, which was developed carefully and considered clinical information together with claims data. Still, it may not fully reflect the true causation of costs by AF and its complications, and could not distinguish which specific complications, e.g. strokes, were truly due to AF or not.

In conclusion, this study analysed real-world AF costs, patient clusters and their cost trajectories. We observed mean annual AF-adjudicated costs of roughly CHF 6,000 per patient and stable relative contributions of different cost categories during five years. Three well-differentiated patient clusters were identified using a hierarchical clustering method: CV-dominated, HF-dominated and IS patients. The cost levels for AF-adjudicated and overall healthcare costs depended on patient cluster but remained again stable over time. CV-dominated patients accrued the highest costs and HF-dominated patients only slightly lower ones, while IS patients had substantially lower costs. These insights may help clinicians and payers to develop an early understanding of the magnitude of to be expected AF-related healthcare costs.

Funding

1

6 7

12

13

- 2 This work is supported by grants of the Swiss National Science Foundation (grant
- 3 numbers 105318_189195 / 1, 33CS30_148474, 33CS30_177520, 32473B_176178, and
- 4 32003B_197524), the Swiss Heart Foundation, the Foundation for Cardiovascular
- 5 Research Basel (FCVR), and the University of Basel.

Acknowledgements

- 8 We thank Lukas Kauer from the health insurance CSS, Pascal Godet from the health
- 9 insurance Sanitas, Beat Brüngger and Andri Signorell from the health insurance
- 10 Helsana, and the health insurance KPT for providing the claims data for this study. The
- 11 full list of Swiss-AF investigators is provided in the supplementary material.

Disclosures

- 14 Dr. Auricchio is a consultant with Abbott, Boston Scientific, Backbeat, Cairdac, Corvia,
- 15 EP Solutions, Medtronic, Microport CRM, Philips, XSpline; he participates in clinical trials
- sponsored by Boston Scientific, Medtronic, Microport CRM, Philips and XSpline; and has
- 17 intellectual properties assigned to Boston Scientific, Biosense Webster, and Microport
- 18 CRM. Dr. Beer reports grant support from the Swiss National Foundation of Science,
- 19 The Swiss Heart Foundation and the Stiftung Kardio; grant support, speakers- and
- 20 consultation fees to the institution from Bayer, Sanofi and Daichii Sankyo. Dr. Bonati
- 21 reports personal fees and nonfinancial support from Amgen, grants from AstraZeneca,
- 22 personal fees and nonfinancial support from Bayer, personal fees from Bristol-Myers
- 23 Squibb, personal fees from Claret Medical, grants from Swiss National Science
- 24 Foundation, grants from University of Basel, grants from Swiss Heart Foundation,
- outside the submitted work. Dr. Conen received consulting fees from Roche Diagnostics.
- and speaker fees from Servier and BMS/Pfizer, all outside of the current work. Dr. Kühne
- 27 reports personal fees from Bayer, personal fees from Böhringer Ingelheim, personal fees
- 28 from Pfizer BMS, personal fees from Daiichi Sankyo, personal fees from Medtronic,
- 29 personal fees from Biotronik, personal fees from Boston Scientific, personal fees from
- 30 Johnson&Johnson, personal fees from Roche, grants from Bayer, grants from Pfizer,
- 31 grants from Boston Scientific, grants from BMS, grants from Biotronik, grants from Daiichi
- 32 Sankyo. Dr. Moschovitis has received consultant fees for taking part to advisory boards
- 33 from Novartis, Boehringer Ingelheim, Bayer, Astra Zeneca and Daiichi Sankyo, all
- 34 outside of the presented work. Dr. Müller reports fellowship and training support from
- 35 Biotronik, Boston Scientific, Medtronic, Abbott/St. Jude Medical, and Biosense Webster;
- 36 speaker honoraria from Biosense Webster, Medtronic, Abbott/St. Jude Medical,
- 37 AstraZeneca, Daiichi Sankyo, Biotronik, MicroPort, Novartis, and consultant honoraria

1 for Biosense Webster, Medtronic, Abbott/St. Jude Medcal, and Biotronik. Dr. Osswald 2 received research grants from the Swiss National Science Foundation and from the 3 Swiss Heart Foundation, research grants from Foundation for CardioVascular Research 4 Basel, research grants from Roche, educational and speaker office grants from Roche, 5 Bayer, Novartis, Sanofi AstraZeneca, Daiichi-Sankyo and Pfizer. Dr. Reichlin has received research grants from the Swiss National Science Foundation, the Swiss Heart 6 7 Foundation, and the sitem insel support fund, all for work outside the submitted study. 8 Speaker/consulting honoraria or travel support from Abbott/SJM, Astra Zeneca, Brahms, 9 Bayer, Biosense-Webster, Biotronik, Boston-Scientific, Daiichi Sankyo, Medtronic, 10 Pfizer-BMS and Roche, all for work outside the submitted study. Support for his 11 institution's fellowship program from Abbott/SJM, Biosense-Webster, Biotronik, Boston-12 Scientific and Medtronic for work outside the submitted study. Dr. Schwenkglenks reports 13 grants from Swiss National Science Foundation, for the conduct of the study; grants and 14 personal fees from Amgen, grants from MSD, grants from Novartis, grants from Pfizer, 15 grants from The Medicines Company, all outside the submitted work. Dr. Serra-Burriel reports grants from the European Commission outside of the present work. Dr. 16 17 Sticherling has received speaker honoraria from Biosense Webster and Medtronic and 18 research grants from Biosense Webster, Daiichi-Sankyo, and Medtronic. The remaining 19 authors have nothing to disclose.

Ethics and Data availability statement

2021

22

23

24

25

26

27

28

29

30

The Swiss-AF study protocol was approved by the local ethics committee (Ethikkommission Nordwest- und Zentralschweiz), and written informed consent was obtained from each participant. The patient informed consent forms state that the data, containing personal and medical information, are exclusively available for research institutions in an anonymized form and are not allowed to be made publicly available. Researchers interested in obtaining the data for research purposes can contact the Swiss-AF scientific lead. Contact information is provided on the Swiss-AF website (http://www.swissaf.ch/contact.htm). Authorization of the responsible ethics committee is mandatory before the requested data can be transferred to external research institutions.

References

- 2 1. Patel, N. J., Atti, V., Mitrani, R. D., Viles-Gonzalez, J. F. & Goldberger, J. J. Global rising trends of atrial fibrillation: a major public health concern. *Heart* **104**, 1989–1990 (2018).
- 5 2. Krijthe, B. P. *et al.* Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. *European Heart Journal* **34**, 2746–2751 (2013).
- 8 3. Miyasaka, Y. *et al.* Secular Trends in Incidence of Atrial Fibrillation in Olmsted County, Minnesota, 1980 to 2000, and Implications on the Projections for Future Prevalence. *Circulation* **114**, 119–125 (2006).
- Conen, D. *et al.* Risk of Death and Cardiovascular Events in Initially Healthy
 Women With New-Onset Atrial Fibrillation. *JAMA* 305, 2080–2087 (2011).
- Stewart, S., Murphy, N. F., Walker, A., McGuire, A. & McMurray, JJ. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. *Heart* 90, 286–292 (2004).
- Wodchis, W. P., Bhatia, R. S., Leblanc, K., Meshkat, N. & Morra, D. A Review of
 the Cost of Atrial Fibrillation. *Value in Health* 15, 240–248 (2012).
- Ball, J., Carrington, M. J., McMurray, J. J. V. & Stewart, S. Atrial fibrillation: Profile
 and burden of an evolving epidemic in the 21st century. *International Journal of Cardiology* 167, 1807–1824 (2013).
- Wolowacz, S. E., Samuel, M., Brennan, V. K., Jasso-Mosqueda, J. G. & van Gelder, I. C. The cost of illness of atrial fibrillation: a systematic review of the recent literature. *Europace* **13**, 1375–1385 (2011).
- Wong, C. X., Brooks, A. G., Leong, D. P., Roberts-Thomson, K. C. & Sanders, P.
 The Increasing Burden of Atrial Fibrillation Compared With Heart Failure and
 Myocardial Infarction: A 15-Year Study of All Hospitalizations in Australia. *Arch Internal Medicine* 172, 739–741 (2012).
- 28 10. Bhat, A. *et al.* Drivers of hospitalization in atrial fibrillation: A contemporary review. 29 *Heart Rhythm* **17**, 1991–1999 (2020).
- 30 11. Steinberg, B. A. *et al.* Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). *American Heart Journal* **167**, 735-742.e2 (2014).
- Inohara, T. et al. Association of Atrial Fibrillation Clinical Phenotypes With
 Treatment Patterns and Outcomes: A Multicenter Registry Study. JAMA
 Cardiology 3, 54–63 (2018).
- 13. Lip, G., Nieuwlaat, R., Pisters, R., Lane, D. & Crijns, H. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. *Chest* **137**, 263–272 (2010).
- 40 14. Conen, D. *et al.* Design of the Swiss Atrial Fibrillation Cohort Study (Swiss-AF): 41 structural brain damage and cognitive decline among patients with atrial 42 fibrillation. *Swiss Medical Weekly* **147**, (2017).

- 1 15. Conen, D. *et al.* Relationships of Overt and Silent Brain Lesions With Cognitive Function in Patients With Atrial Fibrillation. *J Am Coll Cardiol* **73**, 989–999 (2019).
- 3 16. SwissDRG. https://www.swissdrg.org/de/akutsomatik/swissdrg-system-1002021 (2021).
- Huber, C. A., Szucs, T. D., Rapold, R. & Reich, O. Identifying patients with chronic conditions using pharmacy data in Switzerland: an updated mapping approach to the classification of medications. *BMC Public Health* **13**, 1–10 (2013).
- 8 18. Hastie, T., Tibshirani, R. & Friedman, J. Springer Series in Statistics The Elements of Statistical Learning Data Mining, Inference, and Prediction.
- 10 19. Reinhold, T., Lindig, C., Willich, S. N. & Brüggenjürgen, B. The costs of atrial fibrillation in patients with cardiovascular comorbidities--a longitudinal analysis of German health insurance data. *Europace* **13**, 1275–1280 (2011).
- Zoni-Berisso, M. *et al.* The cost of atrial fibrillation in Italy: a five-year analysis of healthcare expenditure in the general population. From the Italian Survey of Atrial Fibrillation Management (ISAF) study. *European Review for Medical and Pharmacological Sciences* 21, 175–183 (2017).
- 17 21. Kim, M., Lin, J., Hussein, M., Kreilick, C. & Battleman, D. Cost of atrial fibrillation 18 in United States managed care organizations. *Advances in Therapy* **26**, 847–857 19 (2009).
- 20 22. Ringborg, A. *et al.* Costs of atrial fibrillation in five European countries: Results from the Euro Heart Survey on atrial fibrillation. *Europace* **10**, 403–411 (2008).
- 22 23. Becker, C. Cost-of-illness studies of atrial fibrillation: methodological considerations. *Expert Review of Pharmacoeconomics & Outcomes Research* **14**, 661–684 (2014).
- 24. Johnsen, S. P., Dalby, L. W., Täckström, T., Olsen, J. & Fraschke, A. Cost of illness of atrial fibrillation: a nationwide study of societal impact. *BMC Health Services Research* **17**, 1–8 (2017).
- 25. Kim, M., Johnston, S., Chu, B., Dalal, M. R. & Schulman, K. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States.

 30. *Circulation. Cardiovascular Quality and Outcomes* **4**, 313–320 (2011).
- 31 26. Inohara, T. *et al.* A Cluster Analysis of the Japanese Multicenter Outpatient Registry of Patients With Atrial Fibrillation. *The American Journal of Cardiology* 33 **124**, 871–878 (2019).
- 34 27. Suzuki, S. *et al.* Identifying risk patterns in older adults with atrial fibrillation by hierarchical cluster analysis: A retrospective approach based on the risk probability for clinical events. *IJC Heart & Vasculature* **37**, 100883 (2021).
- 37 28. Karwath, A. *et al.* Redefining β-blocker response in heart failure patients with sinus
 38 rhythm and atrial fibrillation: a machine learning cluster analysis. *The Lancet* 398,
 39 1427–1435 (2021).
- 40 29. Boccuzzi, S. *et al.* Retrospective study of total healthcare costs associated with chronic nonvalvular atrial fibrillation and the occurrence of a first transient ischemic attack, stroke or major bleed. *Curr Med Res Opin* **25**, 2853–2864 (2009).

1 30. Bennell, M. C. *et al.* Identifying predictors of cumulative healthcare costs in incident atrial fibrillation: A population-based study. *J Am Heart Assoc* **4**, (2015).

Table 1. Baseline characteristics of all included AF patients and each cluster.

	Overall	Cardiovascular Dominated	Isolated Symptomatic	Heart Failure Dominated		
	N 1 024	253	586	185	р	SMD
Characteristics						
Age mean (SD)	73.00 (8.17)	75.39 (6.81)	70.92 (8.30)	76.32 (7.48)	<0.001	0.467
Sex Female N (%)	283 (27.6)	29 (11.5)	177 (30.2)	77 (41.6)	< 0.001	0.48
BMI median [IQR]	26.98 [24.43, 30.52]	28.65 [25.61, 31.94]	26.21 [24.06, 29.72]	27.13 [24.69, 30.81]	<0.001	0.276
Type of AF N (%)					< 0.001	0.508
Paroxysmal	471 (46.0)	97 (38.3)	314 (53.6)	60 (32.4)		
Permanent	243 (23.7)	87 (34.4)	73 (12.5)	83 (44.9)		
Persistent	310 (30.3)	69 (27.3)	199 (34.0)	42 (22.7)		
AF symptoms N (%)	632 (61.8)	125 (49.4)	429 (73.2)	78 (42.2)	< 0.001	0.437
Years since AF Dx mean (SD)	6.33 (7.91)	7.72 (9.21)	5.32 (6.99)	7.66 (8.32)	< 0.001	0.202
CHA ₂ DS ₂ -VASc mean (SD)	3.44 (1.73)	4.90 (1.42)	2.67 (1.48)	3.92 (1.39)	< 0.001	1.036
Prev. Major Bleeding N (%)	61 (6.0)	22 (8.7)	21 (3.6)	18 (9.7)	0.001	0.166
Prev. Stroke or TIA N (%)	212 (20.7)	68 (26.9)	109 (18.6)	35 (18.9)	0.02	0.132
Prev. Sys. Embolism N (%)	60 (5.9)	27 (10.7)	16 (2.7)	17 (9.2)	< 0.001	0.216
Prev. Heart Failure N (%)	254 (24.8)	126 (49.8)	49 (8.4)	79 (42.7)	< 0.001	0.675
Prev. Myocardial Inf. N (%)	161 (15.7)	140 (55.3)	17 (2.9)	4 (2.2)	< 0.001	0.971
Diabetes N (%)	176 (17.2)	96 (37.9)	41 (7.0)	39 (21.1)	<0.001	0.53
Hypertension N (%)	692 (67.6)	222 (87.7)	319 (54.4)	151 (81.6)	< 0.001	0.523
Renal Insufficiency N (%)	213 (20.8)	101 (39.9)	39 (6.7)	73 (39.5)	< 0.001	0.57
Sleep Apnea N (%)	154 (15.0)	63 (24.9)	65 (11.1)	26 (14.1)	< 0.001	0.244
Prev. PTCA or CABG N (%)	288 (28.1)	219 (86.6)	63 (10.8)	6 (3.2)	< 0.001	1.897
Prev. Electroconversion $N\left(\%\right)$	355 (34.7)	80 (31.6)	223 (38.1)	52 (28.1)	0.023	0.142
Prev. PVI N (%)	210 (20.5)	23 (9.1)	176 (30.0)	11 (5.9)	<0.001	0.442
Implanted Device N (%)					<0.001	0.42
No device or Loop recorder	841 (82.1)	183 (72.3)	529 (90.3)	129 (69.7)		

PM	121 (11.8)	37 (14.6)	44 (7.5)	40 (21.6)		
ICD	31 (3.0)	16 (6.3)	8 (1.4)	7 (3.8)		
CRT (ICD)	31 (3.0)	17 (6.7)	5 (0.9)	9 (4.9)		
Medication <i>N (%)</i>						
Antiplateletes	53 (5.2)	37 (14.6)	13 (2.2)	3 (1.6)	<0.001	0.331
Aspirin	171 (16.7)	103 (40.7)	50 (8.5)	18 (9.7)	< 0.001	0.537
Statins	529 (51.7)	228 (90.1)	228 (38.9)	73 (39.5)	< 0.001	0.843
Diuretics	459 (44.8)	177 (70.0)	116 (19.8)	166 (89.7)	< 0.001	1.217
Beta-blockers	726 (70.9)	210 (83.0)	379 (64.7)	137 (74.1)	< 0.001	0.283
Digoxin	39 (3.8)	13 (5.1)	9 (1.5)	17 (9.2)	< 0.001	0.235
Anticoagulation					< 0.001	0.586
None	93 (9.1)	28 (11.1)	55 (9.4)	10 (5.4)		
VKA	414 (40.4)	148 (58.5)	151 (25.8)	115 (62.2)		
DOAC	517 (50.5)	77 (30.4)	380 (64.8)	60 (32.4)		
Comorbidities (PCG; %)						
Acid	397 (38.8)	115 (45.6)	207 (35.4)	75 (40.5)	0.018	0.14
Bone	44 (4.3)	7 (2.8)	22 (3.8)	15 (8.1)	0.015	0.159
Cancer	35 (3.4)	9 (3.6)	17 (2.9)	9 (4.9)	0.438	0.068
Cardiovascular	754 (73.8)	191 (75.8)	417 (71.3)	146 (78.9)	0.085	0.118
Dementia	27 (2.6)	3 (1.2)	16 (2.7)	8 (4.3)	0.127	0.13
Diabetes	122 (11.9)	63 (25.0)	27 (4.6)	32 (17.3)	< 0.001	0.401
Epilepsy	66 (6.5)	22 (8.7)	35 (6.0)	9 (4.9)	0.207	0.103
Glaucoma	103 (10.1)	29 (11.5)	54 (9.2)	20 (10.8)	0.565	0.05
Gout	96 (9.4)	43 (17.1)	27 (4.6)	26 (14.1)	< 0.001	0.274
Hyperlipidemia	425 (41.6)	169 (67.1)	190 (32.5)	66 (35.7)	< 0.001	0.489
Iron deficiency	66 (6.5)	22 (8.7)	27 (4.6)	17 (9.2)	0.021	0.121
Pain	386 (37.8)	105 (41.7)	199 (34.0)	82 (44.3)	0.014	0.141
Psychiatric	266 (26.0)	72 (28.6)	143 (24.4)	51 (27.6)	0.399	0.062
Antipsychotic	16 (1.6)	3 (1.2)	10 (1.7)	3 (1.6)	0.855	0.029
Respiratory	144 (14.1)	44 (17.5)	69 (11.8)	31 (16.8)	0.05	0.107

Rheumatic	406 (39.7)	111 (44.0)	223 (38.1)	72 (38.9)	0.266	0.08
Thyroid	87 (8.5)	20 (7.9)	49 (8.4)	18 (9.7)	0.789	0.042
Sparse	27 (2.6)	8 (3.2)	12 (2.1)	7 (3.8)	0.366	0.069
Socioeconomic						
Education N (%)					<0.001	0.337
Basic	139 (13.6)	25 (9.9)	75 (12.8)	39 (21.1)		
Middle	505 (49.4)	147 (58.1)	258 (44.1)	100 (54.1)		
Advanced	379 (37.0)	81 (32.0)	252 (43.1)	46 (24.9)		
Mother tongue N (%)					0.005	0.213
German	755 (73.7)	203 (80.2)	415 (70.8)	137 (74.1)		
French	141 (13.8)	29 (11.5)	80 (13.7)	32 (17.3)		
Italian	128 (12.5)	21 (8.3)	91 (15.5)	16 (8.6)		
Smoking N (%)					< 0.001	0.295
Never	453 (44.2)	73 (28.9)	290 (49.5)	90 (48.6)		
In the past	495 (48.3)	160 (63.2)	253 (43.2)	82 (44.3)		
Active	76 (7.4)	20 (7.9)	43 (7.3)	13 (7.0)		
Alcohol mean (SD)	1.12 (1.53)	1.08 (1.40)	1.14 (1.52)	1.14 (1.72)	0.845	0.028
Greater Region N (%)					<0.001	0.352
Zurich	125 (12.2)	46 (18.2)	63 (10.8)	16 (8.6)		_
Lake Geneva Region	56 (5.5)	12 (4.7)	28 (4.8)	16 (8.6)		
Espace Mitelland	289 (28.2)	68 (26.9)	166 (28.3)	55 (29.7)		
Northwestern Switzerland	310 (30.3)	84 (33.2)	159 (27.1)	67 (36.2)		
Eastern Switzerland	67 (6.5)	9 (3.6)	48 (8.2)	10 (5.4)		
Southern Switzerland	125 (12.2)	21 (8.3)	89 (15.2)	15 (8.1)		
Central Switzerland	52 (5.1)	13 (5.1)	33 (5.6)	6 (3.2)		20.1/40

Notes: Alcohol in drinks per day. Abbreviations: AF: atrial fibrillation, CABG: coronary artery bypass grafting, CHA₂DS₂-VASc: risk of stroke (for non-valvular atrial fibrillation), CRT: Cardiac resynchronization therapy, DOAC: direct-acting oral anticoagulant, Dx: diagnosis, ICD: Implantable cardioverter defibrillator, IQR: interquartile range, PCG: pharmaceutical cost groups, PM: Pacemaker, Prev.: previous history of, PTCA: Percutaneous transluminal coronary angioplasty, PVI: Pulmonary vein isolation, SD: standard deviation, SMD: standardized mean difference, TIA: transient ischemic attack, VKA: vitamin K antagonist.




Figure 1. Cost compositions and cost trajectory of different outcome variables. A) Composition of mean annual total costs. B) Cost trajectory of total, total inpatient and total outpatient costs during five years of follow-up. C) Composition of mean annual AF-adjudicated total costs. AF treatment costs include AF medication, and stroke / TIA costs include stroke / TIA medication. All cost components include inpatient and outpatient services, except for heart failure. Heart failure costs were calculated only from inpatient services. D) Cost trajectory of AF-adjudicated total, AF-adjudicated total inpatient and AF-adjudicated total outpatient costs during five years of follow-up.

Notes: Abbreviations: adj.: adjudicated, AF: atrial fibrillation.




Figure 2. Cost trajectories by patient clusters. Three patient clusters were identified: Cardiovascular Dominated, Isolated Symptomatic AF, and Heart Failure Dominated. The cost trajectory for different cost outcomes are shown for a follow-up period of five years: A) total costs, B) total AF-adjudicated costs, C) total inpatient costs, D) total AF-adjudicated inpatient costs, E) total outpatient costs, and F) total AF-adjudicated outpatient costs. *Notes:* Abbreviations: adj.: adjudicated, AF: atrial fibrillation.